KILITCH
Kilitch Drugs (India) financials
- Market cap
- ₹650 Cr
- Sector
- Healthcare
What Kilitch Drugs (India) Limited does
Kilitch Drugs (India) Limited manufactures, supplies and markets pharmaceutical formulations across Solid, Liquid and Parenteral dosage forms, including sterile injectables and ophthalmic drops, effervescent tablets and granules, tablets and capsules, OTC nutraceuticals, cosmetics and medical devices. Its Mumbai plant produces small-volume liquid ampoules and vials plus ophthalmic products and has a dedicated dry powder injectable section. Through its Ethiopian subsidiary Kilitch Estro Biotech PLC, it operates the largest Cephalosporin plant in East Africa, making tablets, capsules, injectables and dry powders for suspensions/syrups for African markets. The company sells its branded and generic formulations across Asia, Africa, CIS and Latin America.
Segments
- Injectable (Parenteral)
- Ophthalmic
- OSD (Oral Solid Dosage)
- Cephalosporin
- Nasal Products
- Nutraceuticals
- Medical Devices
- Cosmetics
- Manufacturing plants
- 2 (Mumbai, India; Ethiopia) + 1 under construction (Pen, Maharashtra)
- Export countries
- 49+
- Subsidiaries
- 2 (Monarchy Healthserve Pvt. Ltd.; Kilitch Estro Biotech PLC, Ethiopia)
- Employees
- 187
- Product dosage forms
- Solid, Liquid, Parenteral
- Regulatory accreditations
- FDA Philippines, MOH Cambodia, FMHACA Ethiopia, FDA Ghana, PPB Kenya, NMPB Sudan, MOH Zambia, NAFDAC Nigeria, Rwanda FDA, LMHRA Liberia
Quarterly results
Q1 FY27: revenue up 4.0%, net profit down 13.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47 | 56 | 61 | 43 | 49 +3% | 54 −4% | 90 +46% | 45 +4% |
| EBITDA | 6 | 9 | 15 | 3 | 5 −17% | 6 −30% | 22 +52% | 3 −10% |
| Net profit | 9 | 6 | 10 | 2 | 8 −7% | 4 −23% | 15 +46% | 2 −14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −49.3% 1Y
1Y: ₹366.95 on 10 Sept 2025 → ₹185.97. High ₹400.25 (27 Oct 2025), low ₹124.45 (30 Mar 2026).
Financials, as filed
Revenue grew 19.2% a year over 3 years, FY23 to FY26. Operating margin widened to 15.5%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹139 Cr | ₹154 Cr | ₹198 Cr | ₹235 Cr |
| Operating profit | ₹17 Cr | ₹24 Cr | ₹31 Cr | ₹37 Cr |
| Operating margin | 12.5% | 15.7% | 15.7% | 15.5% |
| Interest | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr |
| Depreciation | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr |
| Net profit | ₹8 Cr | ₹14 Cr | ₹25 Cr | ₹30 Cr |
| Net margin | 6.0% | 8.8% | 12.4% | 12.5% |
| Cash from operations | ₹3 Cr | ₹-2 Cr | ₹18 Cr | ₹24 Cr |
| Free cash flow | ₹-1 Cr | ₹-8 Cr | ₹-29 Cr | ₹-76 Cr |
| ROCE | 10.0% | 13.0% | 16.0% | 13.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹15 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹17 Cr | ₹35 Cr |
| Reserves | ₹112 Cr | ₹124 Cr | ₹136 Cr | ₹160 Cr | ₹248 Cr | ₹245 Cr |
| Borrowings | ₹15 Cr | ₹20 Cr | ₹22 Cr | ₹32 Cr | ₹84 Cr | ₹89 Cr |
| Other liabilities | ₹61 Cr | ₹50 Cr | ₹46 Cr | ₹32 Cr | ₹49 Cr | ₹89 Cr |
| Total liabilities | ₹203 Cr | ₹210 Cr | ₹220 Cr | ₹240 Cr | ₹399 Cr | ₹458 Cr |
| Fixed assets | ₹30 Cr | ₹65 Cr | ₹64 Cr | ₹62 Cr | ₹64 Cr | ₹67 Cr |
| Capital work in progress | ₹65 Cr | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹98 Cr | ₹140 Cr |
| Investments | ₹60 Cr | ₹71 Cr | ₹62 Cr | ₹72 Cr | ₹77 Cr | ₹75 Cr |
| Other assets | ₹47 Cr | ₹71 Cr | ₹90 Cr | ₹100 Cr | ₹160 Cr | ₹176 Cr |
| Total assets | ₹203 Cr | ₹210 Cr | ₹220 Cr | ₹240 Cr | ₹399 Cr | ₹458 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −5.46 pp while the public added +5.34 pp. The shareholder count grew 22% to 12,627.
- Promoters
- 63.8%
- FIIs
- 0.1%
- Public
- 36.1%
Since Jun 2025
- Promoters −5.46 pp
- Public +5.34 pp
- FIIs +0.12 pp
How it drifted, 12 quarters
Over this window promoters fell from 69.2% to 63.8% — −5.5 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 69.2%, Public 30.8%.Dec '23: Promoters 69.2%, Public 30.8%.Mar '24: Promoters 69.2%, Public 30.8%.Jun '24: Promoters 69.2%, Public 30.8%.Sep '24: Promoters 69.2%, Public 30.8%.Dec '24: Promoters 69.2%, Public 30.8%.Mar '25: Promoters 69.2%, Public 30.8%.Jun '25: Promoters 69.2%, Public 30.8%.Sep '25: Promoters 63.8%, Public 36.2%.Dec '25: Promoters 63.8%, Public 36.2%.Mar '26: Promoters 63.8%, Public 36.2%.Jun '26: Promoters 63.8%, FIIs 0.1%, Public 36.1%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Investor Education And Protection Fund Authority newly disclosed 2.29% held
The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Kilitch Drugs (India) Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Kilitch Company (Pharma) Limited | 37.92% | unchanged |
| Bhavin Mukund Mehta | 14.43% | unchanged |
| Mukund Mehta | 6.61% | unchanged |
| Mira Bhavin Mehta | 4.81% | unchanged |
| Dipak Kanayalal Shah | 3.20% | −0.44 pp |
| Investor Education And Protection Fund Authority | 2.29% | newly disclosed |
| Mukul Mahavir Agrawal | 1.34% | unchanged |
| Premilaben Rameshchandra Shah | 1.14% | unchanged |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹186, this stock must grow earnings at 21% every year for 7 years. Our analysis caps realistic growth at ~43%. At that growth it is worth ₹544 — upside of 193%.
- Growth the price implies
- 20.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 42.7% a year
- net profit, FY23–FY26
- The gap
- -0.2 pp
- 193% downside if it only repeats history
Learn to analyse Kilitch Drugs (India) Limited
Guides on how to read this kind of business and the numbers that matter.